Anaptysbio Inc.

5 trials 1 recruiting Commercial sponsor

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

1 Recruiting

4 Completed trials

16 Countries active

5 Unique IMPs

100% Results reported

Phase II

Phase I

Phase II: 4 Phase I: 1

100%

4 of 4 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Eosinophilic oesophagitis 1 Rheumatoid arthritis 1

Top IMPs

ANB032 2 ROSNILIMAB 2

All trials

5 total

Efficacy and Safety of ANB032 in the Treatment of Subjects with Atopic Dermatitis Not authorised

2023-503522-40-00 Phase II 2 countries ANB032
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ANB033 Recruiting

2024-520409-38-00 Phase I 3 countries
Efficacy and Safety of Rosnilimab in Subjects with Ulcerative Colitis Ended

2023-508679-34-00 Phase II 10 countries ROSNILIMAB
Efficacy and Safety of ANB032 in the Treatment of Subjects with Atopic Dermatitis Ended

2023-503522-40-01 Phase II 2 countries ANB032
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to… Ended

2023-504564-42-00 Phase II 9 countries ROSNILIMAB

Showing 1–5 of 5 trials

← All sponsors A–Z